|
Real-time Estimate
Tradegate
11:19:59 2026-09-14 EDT
|
5-day change | 1st Jan Change | ||
| 121.01 EUR | +2.07% |
|
-13.94% | +0.27% |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease (September 11) | RE |
| 09-11 | US FDA approves Scholar Rock's muscle weakness drug | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 994B | |||||
| 640B | - | - | - | ||
| 454B | |||||
| 337B | |||||
| 261B |
- Stock Market
- Stocks
- NOVN Stock
- NOT Stock
- Charts Novartis AG
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
